China: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection...

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

On January 23, 2025, the Anti-Monopoly and Anti-Unfair Competition Commission under China's State Council officially released the PRCAnti-Monopoly Guidelines for the Pharmaceutical Sector...

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

在全球化背景之下，中国医药企业正站在创新与合作的新风口，迎接前所未有的发展契机。与此同时，海外投资者与医药企业亦在敏锐捕捉投$

China Healthcare

HK

Han Kun Law Offices

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

《关于药品领域的反垄断指南》解读：药企反垄断风险"划重点"

China Healthcare

AB

AnJie Broad Law Firm

China On The Move: Lessons From China's 2024 National Negotiation Of Drug Prices

China Healthcare

GT

Greenberg Traurig, LLP

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

Circular On The Work Relating To The Implementation Of GB 9706.1-2020 And Supporting Concurrent Standards And Special Standards

China Healthcare

CC

CMS, China

Measures For Supervision And Administration Of The Quality Of Drug Supply And Use

China Healthcare

CC

CMS, China

Further Strengthening The Supervision Of Entrusted Manufacturing Of Medical Devices: Key Takeaways From NMPA's New Notice

China Healthcare

CC

CMS, China

Supreme People's Court Issued Interpretation On Punitive Damages For Food And Drug Disputes

China Healthcare

CC

CMS, China

China outbound investment: Trends and outlooks.

A

Acclime

知识产权海外侵权风险与纠纷时有发生，此局何解？

CP

CCPIT Patent & Trademark Law Office

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

讲好知识产权中国故事——对话贸促会专商所知识产权服务团队

CP

CCPIT Patent & Trademark Law Office

网络敲诈勒索的法律规制与最高法典型案例解析——以刑法适用与司法实践为视角

AB

AnJie Broad Law Firm

Food and Drugs Law

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Implementing Measures and Working Procedures for Drug Clinical Trial Data Protection...

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

On January 23, 2025, the Anti-Monopoly and Anti-Unfair Competition Commission under China's State Council officially released the PRCAnti-Monopoly Guidelines for the Pharmaceutical Sector...

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

转用发明创造性浅析

CP

CCPIT Patent & Trademark Law Office

从"AB酶"系列案件看商标法第十条一款七项的适用

CP

CCPIT Patent & Trademark Law Office

《关于药品领域的反垄断指南》解读：药企反垄断风险"划重点"

China Healthcare

AB

AnJie Broad Law Firm

Application Of Bioisosterism In The Judgment Of Inventiveness

AC

AFD China

See more

Life Sciences, Biotechnology & Nanotechnology

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

在全球化背景之下，中国医药企业正站在创新与合作的新风口，迎接前所未有的发展契机。与此同时，海外投资者与医药企业亦在敏锐捕捉投$

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

Application Of Bioisosterism In The Judgment Of Inventiveness

AC

AFD China

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

医药企业申请商标的注意事项

CP

CCPIT Patent & Trademark Law Office

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

See more

Healthcare

里程碑式判决：经营者集中行政诉讼"第一案"代理有感

某某药业有限公司（"某某药业公司"）与北京某药业有限公司（"北京某药业公司"）之间就股权交易的争议由来已久。双方争议涉及股权买卖纠纷

China Anti-trust

AB

AnJie Broad Law Firm

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

In December 2024, the State Council issued the "Opinions on Comprehensively Deepening the Reform of the Supervision of Drugs and Medical Devices to Promote the High-Quality Development.

R

Rouse

China Newsletter | Q4 2024/Issue No. 62

On Dec. 10, 2024, the State Administration for Market Regulation released the Guidelines for the Review of Horizontal Business Concentrations (Guidelines).

China International

GT

Greenberg Traurig, LLP

China Unveils New Anti-Monopoly Guidelines For The Pharmaceutical Sector

China Anti-trust

JD

Jones Day

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

China Tightens The Reins: Anti-Corruption Compliance Expectations For Companies In The Healthcare Sector

RG

Ropes & Gray LLP

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

China's New Draft Administrative Measures For Management Of Medical Representatives

China Healthcare

AP

Arnold & Porter

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More